Recently , in order to re-estimate sample size and examine the efficacy of the DC vaccine . the interim analysis was performed by an independent data monitoring committee , this analysis contained: 11 cases in the placebo group and 11 cases in the control group. According to interim results : 86% of patients had achieved its primary endpoint events with minimal adverse events. However , our preliminary data is too unreliable to conclude anything further about the effency of DC vaccine: some variability need to be included in the analysis and balanced between two groups , such as the immune response, residual tumor volume, the molecular subtype of GBM . Accordingly , we made some modifications to the original plan, and are currently recruiting new participants.